​​​​​​​Michael Humphries

MD, FRCP FHKAM

SVP

Chief Medical Officer

• 30+ years in global/Asia-Pacific development

• 50+ NDA approvals

​​​​​​​Jonathan Zhu

MD, EMBA

SVP

Chief Commercial Officer

• 30+ years in commercialization

• Former China Head of Sales & Marketing at Celgene, Sanofi, and Novartis

​​​​​​​Jean Zhang

MD

VP

Clinical Operations

• 30+ years at Novartis, Pfizer, and AstraZeneca

• Expertise in operations, PV, and QA

​​​​​​​Yuzhi Hu

JD, PharmD, MPH

VP

Chief Legal Officer

• Former FDA professional and Sidley Austin attorney

• Cross-border pharma legal and licensing expert

​​​​Regulatory strategy is a defining strength at Aimabs. Our leadership has first-hand experience within top global agencies and deep expertise navigating China’s evolving regulatory landscape. This dual perspective allows us to de-risk development, accelerate timelines, and align programs with global standards from the earliest stages.

• Dual-market insight: Our Founder & CEO, Dr. Yaping Wang, is a former U.S. FDA Senior Reviewer (Oncology Center of Excellence) and a trusted advisor to China’s CDE/NMPA. We bring strong command of FDA, NMPA, and ICH requirements, with practical guidance on emerging policy trends.

• Cross-border strategic planning: We design clinical strategies and submission packages built to satisfy multi-region expectations, helping partners reduce rework and maximize global optionality.

• Quality and compliance: Our globally aligned Quality Management System supports inspection readiness, data integrity, and long-term compliance across ICH, FDA, and NMPA standards.

​​​​Aimabs brings decades of hands-on experience across all stages of drug development—from early discovery through late-stage validation and launch preparation. We combine scientific rigor, clinical insight, and operational excellence to improve execution quality and increase probability of success.

• Clinical development leadership: Dr. Michael Humphries (SVP & Chief Medical Officer) has 30+ years of global and Asia-Pacific development experience and has contributed to 50+ NDA approvals in China and international markets.

• Operational excellence: Dr. Jean Zhang (VP, Clinical Operations) brings 30+ years of leadership experience at Novartis, Pfizer, and AstraZeneca, with expertise in clinical quality, pharmacovigilance, and trial execution across regions.

• AI-enabled acceleration: We apply AI and machine learning to enhance trial design, patient recruitment strategy, and data analytics—accelerating readiness for global out-licensing and improving efficiency for Greater China development.

​​​​Aimabs partners with CiNS, a leading oncology/hematology-focused commercial organization in Greater China, trusted by multinational companies including Eli Lilly, Pierre Fabre, and Otsuka.

• Market access & coverage: Established footprint across 400+ leading oncology hospitals and 200+ hematology hospitals, supporting broad access to specialty care.

• Sales & launch execution: 150+ specialized commercial professionals supported by cross-functional infrastructure (marketing, PV, RA) to enable high-quality launches.

• Operational readiness: Mature import/trade capabilities, supply chain coordination, and tender management expertise to support long-term growth in China.